Anti-Toxoplasma Activity of Tellurium Oxide (TeO₂) Nanoparticle on *Toxoplasma gondii* In vitro

Amir KarimiPourSaryazdi¹, Fatemeh Ghaffarifar^{1,*}, Mohammad Barati² and Roya Omid¹

¹Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

²Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran

*Corresponding author: Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Email: ghaffarifar@yahoo.com

Received 2021 June 07; Accepted 2021 October 25.

Abstract

Background: *Toxoplasma gondii* is an obligate intracellular parasite in humans and many warm-blooded animals worldwide.

Objectives: This study aimed to investigate the different antiparasitic effects of tellurium oxide (TeO₂) nanoparticles against *T. gondii*.

Methods: In this study, we used tachyzoite assay (ocular counting test) to determine the lethal effect of tellurium nanoparticles on parasites. Toxic effects of nanoparticles on macrophages were also evaluated using MTT assay. The type of parasitic cell death (necrosis or apoptosis) was determined by flow cytometric analysis.

Results: According to the examination of the parasites by light microscopy, TeO₂ nanoparticles had destructive and lethal effects on *T. gondii*. The results of the MTT assay showed that the toxic effects on macrophages were more significant at high concentrations (400 µg/mL). Flow cytometric analysis also estimated the percentage of apoptosis (primary and secondary) of the parasites at 56.97%.

Conclusions: According to the findings, tellurium Oxide nanoparticles have a toxic effect on *T. gondii* and lead to apoptosis in this parasite. This research boosts different tests in another parasite.

Keywords: Tachyzoite, *Toxoplasma gondii*, Tellurium Oxide Nanoparticles, Flow Cytometry, MTT assay

1. Background

Toxoplasma gondii is an obligate intracellular parasite of members of apicomplexan order. This parasite is the most common parasitic infection in humans and many warm-blooded animals in the world (1, 2). Infection by this parasite in developing countries is estimated between 30 to 60 percent (3). About one-third of the world's population is infected with this parasite (1, 4). Humans and warm-blooded animals are intermediate hosts for *T. gondii*. Cats are playing a definitive host role in this parasitic cycle. This parasite forms cysts in various tissues of intermediate hosts and has sexual procreation in the intestine cells of the definitive host. *Toxoplasma gondii* is transmitted through sporulated oocysts excreted by cats, fruits, water, and soil contaminated with oocyst (5-7). This disease in people with a healthy immune system has mild and transient symptoms such as fever, enlarged lymph nodes, or no symptoms at all. But in pregnant women who are in their first pregnancy, it is dangerous and can be transmitted to the infant. In infants, it causes severe symptoms in brain problems such as microcephaly. Other groups at risk are AIDS, malignant problems, cancer patients, and so on (8-

10). Studies show that there are several risk factors for toxoplasmosis, such as contact with soil, residence in a rural region, consumption of drinking water, etc. Therefore, military personnel are exposed to the infection during operations and maneuvers due to the lack of access to healthy drinking water and contact with soil (11).

The first-line drugs for this parasitic disease are sulfadiazine and pyrimethamine, which have various side effects, including bone marrow suppression and parasite drug resistance. We are looking for drugs with the least side effects on patients and the most effect on parasitic bradyzoites phase and cysts in body tissues (12). In recent years, nanotechnology has been used to diagnose and treat various diseases. The materials produced include microcapsules, conjugates, nanocomposites, and nanoparticles (13). Antiparasitic compounds in the form of nanosuspension, such as atovaquone nanosuspension, have a stronger effect on absorption and killing of more parasites than conventional drugs (14-16). In a research conducted by KarimiPourSaryazdi et al., the effects of silver nanoparticles on *Toxoplasma* parasites were evaluated. Silver nanoparticles have lethal effects on the parasite, leading to about 55% of

apoptosis in *Toxoplasma* parasite (17). In another experiment performed by Tavakoli, the effect of manganese oxide (Mn_2O_3) nanoparticles on *Leishmania* was investigated, which resulted in lethal effects of the parasite at different concentrations. The results were confirmed by MTT assay, flow cytometry, and promastigote counting tests (18). Nanoparticles have various properties, including the production of free radicals that lead to the destruction of infectious organisms. With very small size, they can cross membrane barriers to exert their effects inside the cell, including the prevention of some intracellular chemical reactions (19, 20).

2. Objectives

This study aimed to investigate the different antiparasitic effects of tellurium oxide (TeO_2) nanoparticles using different tests such as tachyzoite assay, MTT assay, and flow cytometry.

3. Methods

3.1. Synthesis of Silver Nanoparticles

Tellurium oxide (TeO_2) NPs were synthesized by the Department of Pharmaceutical Biotechnology Research and the Research Center for Pharmaceutical Sciences, Faculty of Pharmacy, Tarbiat Modares University, Tehran. Different concentrations of nanoparticles (400, 200, 100, 50, 25, 12.5, 6.25 $\mu\text{g}/\text{mL}$) were prepared for MTT assay and tachyzoite assay.

3.2. Preparation of *Toxoplasma gondii* (RH Strain)

Toxoplasma gondii (RH strain) was prepared by Tarbiat Modares University, Department of Parasitology. To proliferate the parasite and preserve it, we injected the parasite into the peritoneum of BALB/c mice. When the parasite multiplied enough, it caused clinical symptoms in mice, including fever, swollen lymph nodes, and closed eyes. We injected sterile physiological serum into the mice peritoneum with 2.5 mL syringe to suspend the parasites in the serum. Physiological serum containing the parasite was removed from the peritoneum with syringe (21).

3.3. Tachyzoite Assay

For this experiment, different concentrations of nanoparticles (400, 200, 100, 50, 25, 12.5, 6.25 $\mu\text{g}/\text{mL}$) were prepared in microtiter plate (MP). Two wells were considered for control drugs, sulfadiazine, and pyrimethamine, and one well was used as a control (parasite without any drug). The solution was then centrifuged (1,000 g), and 6×10^5 tachyzoites (counted with hemocytometer slide)

were added to all wells. Tachyzoites were explored for morphology and number of parasites in each well three, six, and 24 hours after exposure to nanoparticles. Each test was repeated three times (21).

3.4. MTT Assay for Macrophage

This experiment was used to evaluate the effects of nanoparticles and to evaluate cytotoxicity. To prepare MTT solution, five micrograms of MTT powder (Tetrazolium salt) (Gibco, Germany) were dissolved in 1 mL of PBS solution in the dark condition. We added in three separate plates 100 μL of RPMI 1640 (Gibco, Germany) solution plus 10% FBS (Gibco, Germany) composed with streptomycin (100 U/mL) (Gibco BRL) and penicillin (100 U/mL) (Gibco BRL) containing macrophages in each well. Also, we added different concentrations of nanoparticles in the volume of 100 microliters to all wells except the negative control well (macrophages without nanoparticles and drugs). We incubated them at 37°C with 5% CO_2 . After 24 hours, the surface fluid of the wells was removed, and 20 microliters volume of MTT solution was added to all wells and incubated again for four hours. Subsequently, 100 μL of DMSO solution was added to the wells and placed in an ELISA reader with 540 nm wavelength to calculate the wells absorption. We performed all steps of this experiment in a dark room (22, 23).

3.5. Flow Cytometry

In this research, flow cytometry technique with double staining [annexin V (V-FLUOS) and propidium iodide (PI)] was used to evaluate the type of cell death (apoptosis or necrosis). In this technique, we have four parts in the output of the device results. The different parts are as follow: the lower right was stained with annexin V (apoptotic cells), the upper right was stained with annexin V and PI (delayed or secondary apoptosis), the lower left was colorless (living cells), and the upper left was stained PI (necrosis cells) (24). In our research, Annexin V-FITC apoptosis (Bio vision) kit was used for flow cytometry. According to the kit instructions, we exposed 2×10^5 tachyzoites with 93 $\mu\text{g}/\text{mL}$ concentration (IC50 concentration) of tellurium oxide nanoparticles. After 24 hours of incubation at 24°C, we first added 500 μL of buffer and placed the samples on the ice complex for 15 minutes. In the next step, after adding five μL of PI and Annexin V, the samples were explored by flow cytometry device.

4. Results

4.1. Tachyzoite Assay

Tachyzoites were counted with a light microscope at 3, 6, and 24 hours, and the results are plotted in Figure 1. The

IC50 concentration of TeO₂ nanoparticles in this study was estimated at 93 $\mu\text{g/mL}$, according to ocular count. According to this experiment, it was found that nanoparticles in high concentrations have a more lethal effect on the parasites. Also, the longer the parasite is exposed to nanoparticles, the greater the lethal effect. The results of light microscopy showed deformation of parasites exposed to nanoparticle concentrations.

Figure 1. Exposure of different concentrations of nanoparticles to tachyzoites in 3, 6, 24 hours (Graph shows the standard deviation and mean and quantity is $\times 10^4$). There was a significant difference between the control group and the other groups ($P < 0.05$).

4.2. MTT Assay for Macrophage

The results of this experiment showed that concentrations such as 400 $\mu\text{g/mL}$ was the most toxic effect on macrophages. At concentrations close to the IC₅₀ of the parasite, most macrophages were alive. More information can be seen in Figure 2.

Figure 2. Exposure of different concentrations of nanoparticles to macrophage cells in 24 hours (graph shows viability percentage).

4.3. Flow Cytometric Analysis

This test was performed to evaluate apoptosis and necrosis. At 93 $\mu\text{g/mL}$ of nanoparticle, the percentages

of apoptotic (primary and secondary), necrotic, and living cells were 56.97, 6.61, and 36.4%, respectively. In the control group, the percentage of apoptotic (primary and secondary), necrotic, and living cells were 0.78, 0.02, and 99.2%, respectively (Figure 3).

Figure 3. Flow cytometric analyses, exposure of the parasite to 93 $\mu\text{g/mL}$ concentration of nanoparticles in 24 hours; Right top, late apoptosis; Right bottom, primary apoptosis; Left bottom, alive cells; and Left top, necrosis.

5. Discussion

Toxoplasma gondii is a parasite with high prevalence in developing countries (about 30 to 60%) (3). About one-third of the world's population is infected with this parasite (1, 4). Routine anti-*Toxoplasma gondii* drug therapy cannot eradicate parasitic cysts. Immunocompromised patients cannot tolerate these drugs (12). The first-line drugs for the treatment and prevention of toxoplasmosis diseases are pyrimethamine and sulfadiazine. These drugs have various side effects, including neutropenia, leukopenia, thrombocytopenia, severe platelet count, blood disorders, allergic reactions, elevated serum creatinine, and elevated serum liver enzymes (25). The aim of this study was to investigate the destructive effects of tellurium oxide (TeO₂) nanoparticles on *Toxoplasma gondii* tachyzoites *in vitro*. According to the count of tachyzoites with hemocytometer slide and light microscope, the lethal effect of nanoparticles increases after exposing the parasites to different concentrations of nanoparticles (particularly high concentrations). In this study, the IC₅₀ was 93 $\mu\text{g/mL}$. Also, we used MTT assay to investigate the possible toxic effect of nanoparticles on macrophages. We found that the survival rate of macrophages is high at low nanoparticle concentrations and has a little toxic effect on macrophages. The present research is the first research in this field, and resemblance research has not been performed using TeO₂ nanoparticles on *T. gondii*. A study published in 2012 investigated anticancer effects of tellurium-complex compounds (AS101 and SAS). These compounds induced their

antitumor and anticancer effects by inhibiting cysteine proteases e.g., cathepsin B, inhibiting tumor marker proteins, survivin, and constraining tumor e.g., IL-10 production (26). In our study, TeO₂ nanoparticles led to 56.97% of apoptosis in *T. gondii* parasites. The nanoparticle induces apoptosis by activating the enzyme caspase-3. A study by Pandey in 2016 evaluated the effects of platinum tellurium nanowires with lasers on cancer cells such as A549. Tumor growth was significantly reduced after photothermal treatment through a combination of TePt and laser nanoparticles. Flow cytometry showed that it killed many cancer cells. Therefore, the importance of these new nanomaterials for the photothermal treatment of cancer was proven (27).

5.1. Conclusions

According to the findings of this study, TeO₂ nanoparticles have a toxic effect on *Toxoplasma gondii* and led to apoptosis in this parasite. We suggest that our research be conducted on other parasites.

Footnotes

Authors' Contribution: Study concept and design, Amir KarimiPourSaryazdi (first name), and Mohammad Barati; Corresponding author, Fatemeh Ghaffarifar; Statistical analysis, Roya Omid.

Conflict of Interests: The authors declared no potential conflict of interests.

Ethical Approval: IR.AJAUMS.REC.1400.112.

Funding/Support: Tarbiat Modares University supported this study.

References

- Dubey JP. The history of *Toxoplasma gondii*—the first 100 years. *J Eukaryot Microbiol.* 2008;**55**(6):467–75. doi: [10.1111/j.1550-7408.2008.00345.x](#). [PubMed: [19120791](#)].
- Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. *Clin Microbiol Rev.* 2012;**25**(2):264–96. doi: [10.1128/CMR.05013-11](#). [PubMed: [22491772](#)]. [PubMed Central: [PMC3346298](#)].
- Foroutan-Rad M, Khademvatan S, Majidani H, Aryamand S, Rahim F, Malehi AS. Seroprevalence of *Toxoplasma gondii* in the Iranian pregnant women: A systematic review and meta-analysis. *Acta Trop.* 2016;**158**:160–9. doi: [10.1016/j.actatropica.2016.03.003](#). [PubMed: [26952970](#)].
- Ghaffari AD, Dalimi A, Ghaffarifar F, Pirestani M. Structural prediction and antigenic analysis of ROP16 protein utilizing immunoinformatics methods in order to identification of a vaccine against *Toxoplasma gondii*: An in silico approach. *Microb Pathog.* 2020;**142**:104079. doi: [10.1016/j.micpath.2020.104079](#). [PubMed: [32084578](#)].
- Foroutan-Rad M, Majidani H, Dalvand S, Daryani A, Kooti W, Saki J, et al. Toxoplasmosis in Blood Donors: A Systematic Review and Meta-Analysis. *Transfus Med Rev.* 2016;**30**(3):116–22. doi: [10.1016/j.tmr.2016.03.002](#). [PubMed: [27145927](#)].
- Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis: A systematic review. *Bull World Health Organ.* 2013;**91**(7):501–8. doi: [10.2471/BLT.12.111732](#). [PubMed: [23825877](#)]. [PubMed Central: [PMC3699792](#)].
- Wang ZD, Liu HH, Ma ZX, Ma HY, Li ZY, Yang ZB, et al. Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis. *Front Microbiol.* 2017;**8**:389. doi: [10.3389/fmicb.2017.00389](#). [PubMed: [28337191](#)]. [PubMed Central: [PMC5343064](#)].
- Abdoli A, Barati M, Dalimi A, Pirestani M, Hoseini Shokouh SJ. Toxoplasmosis Among Patients with Immunocompromising Conditions: A Snapshot. *J Arch Mil Med.* 2016;**4**(4). e41832. doi: [10.5812/jamm.41832](#).
- Abdoli A, Barati M, Pirestani M, Dalimi A. Screening of toxoplasmosis in cancer patients: A concern. *Trop Doct.* 2019;**49**(1):31–4. doi: [10.1177/0049475518801618](#). [PubMed: [30270766](#)].
- Ghaffari AD, Dalimi A. Molecular identification of *Toxoplasma gondii* in the native slaughtered cattle of Tehran province, Iran. *J Food Qual Hazards Control.* 2019;**6**:153–61.
- Kolbekova P, Kourbatova E, Novotna M, Kodym P, Fleg J. New and old risk-factors for *Toxoplasma gondii* infection: prospective cross-sectional study among military personnel in the Czech Republic. *Clin Microbiol Infect.* 2007;**13**(10):1012–7. doi: [10.1111/j.1469-0691.2007.01711.x](#). [PubMed: [17617185](#)].
- Antczak M, Dzitko K, Dlugonska H. Human toxoplasmosis—Searching for novel chemotherapeutics. *Biomed Pharmacother.* 2016;**82**:677–84. doi: [10.1016/j.biopha.2016.05.041](#). [PubMed: [27470411](#)].
- Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. *Adv Drug Deliv Rev.* 2003;**55**(3):329–47. doi: [10.1016/s0169-409x\(02\)00228-4](#). [PubMed: [12628320](#)].
- Dunay IR, Heimesaat MM, Bushrab FN, Muller RH, Stocker H, Arasteh K, et al. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. *Antimicrob Agents Chemother.* 2004;**48**(12):4848–54. doi: [10.1128/AAC.48.12.4848-4854.2004](#). [PubMed: [15561866](#)]. [PubMed Central: [PMC529229](#)].
- Scholer N, Krause K, Kayser O, Muller RH, Borner K, Hahn H, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. *Antimicrob Agents Chemother.* 2001;**45**(6):1771–9. doi: [10.1128/AAC.45.6.1771-1779.2001](#). [PubMed: [11353624](#)]. [PubMed Central: [PMC90544](#)].
- Shubar HM, Dunay IR, Lachenmaier S, Dathe M, Bushrab FN, Mauludin R, et al. The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis. *J Drug Target.* 2009;**17**(4):257–67. doi: [10.1080/10611860902718680](#). [PubMed: [19255896](#)].
- KarimiPourSaryazdi A, Tavakoli P, Barati M, Ghaffarifar F, Dalir Ghaffari A, KarimiPourSaryazdi Y. Anti-Toxoplasma Effects of Silver Nanoparticles Based on Ginger Extract: An in Vitro Study. *J Arch Mil Med.* 2020;**7**(4). e104248. doi: [10.5812/jamm.104248](#).
- Tavakoli P, Ghaffarifar F, Delavari H, Shahpari N. Efficacy of manganese oxide (Mn₂O₃) nanoparticles against *Leishmania major* in vitro and in vivo. *J Trace Elem Med Biol.* 2019;**56**:162–8. doi: [10.1016/j.jtemb.2019.08.003](#). [PubMed: [31473559](#)].
- Adeyemi OS, Whiteley CG. Interaction of metal nanoparticles with recombinant arginine kinase from *Trypanosoma brucei*: thermodynamic and spectrofluorimetric evaluation. *Biochim Biophys Acta.* 2014;**1840**(1):701–6. doi: [10.1016/j.bbagen.2013.10.038](#). [PubMed: [24184914](#)].
- Alajmi RA, Al-Megrin WA, Metwally D, Al-Subaie H, Altamrah N, Barakat AM, et al. Anti-Toxoplasma activity of silver nanoparticles green synthesized with *Phoenix dactylifera* and *Ziziphus spina-christi* extracts which inhibits inflammation through liver regulation of cytokines in Balb/c mice. *Biosci Rep.* 2019;**39**(5). doi: [10.1042/BSR20190379](#). [PubMed: [30992387](#)]. [PubMed Central: [PMC6522717](#)].

21. Ghaffarifar F, KarimiPourSaryazdi A, Ghaffari AD, Tavakoli P, Barati M, Rasekhi A, et al. Anti-Toxoplasma Effects of Artemisia aucheri Extract in Vitro. *Paramedical Sciences and Military Health*. 2020;**15**(1):26–34.
22. Kadkhodamasoum S, Bineshian F, KarimiPour A, Tavakoli P, Foroutan M, Ghaffarifar F, et al. Comparison of the Effects of Sambucus ebulus Leaf and Fruit Extracts on Leishmania major In Vitro. *Infect Disord Drug Targets*. 2021;**21**(1):49–54. doi: [10.2174/1871526520666191220114540](https://doi.org/10.2174/1871526520666191220114540). [PubMed: [31858914](https://pubmed.ncbi.nlm.nih.gov/31858914/)].
23. Bineshian F, Saryazdi AK, Ghaffarifar F, Raeeni MGN, Pazoki R. The Effect of Aqueous Extract of Artemisia aucheri Seed on Acanthamoeba In vitro. *J Pharm Res Int*. 2020;**31**(6):1–10. doi: [10.9734/jpri/2019/v31i630367](https://doi.org/10.9734/jpri/2019/v31i630367).
24. KarimiPourSaryazdi A, Ghaffarifar F, Dalimi A, Dayer MS. In-vitro and in-vivo comparative effects of the spring and autumn-harvested Artemisia aucheri Bioss extracts on Leishmania major. *J Ethnopharmacol*. 2020;**257**:112910. doi: [10.1016/j.jep.2020.112910](https://doi.org/10.1016/j.jep.2020.112910). [PubMed: [32344159](https://pubmed.ncbi.nlm.nih.gov/32344159/)].
25. Silveira C, Belfort RJ, Muccioli C, Holland GN, Victora CG, Horta BL, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. *Am J Ophthalmol*. 2002;**134**(1):41–6. doi: [10.1016/S0002-9394\(02\)01527-1](https://doi.org/10.1016/S0002-9394(02)01527-1). [PubMed: [12095806](https://pubmed.ncbi.nlm.nih.gov/12095806/)].
26. Sredni B. Immunomodulating tellurium compounds as anti-cancer agents. *Semin Cancer Biol*. 2012;**22**(1):60–9. doi: [10.1016/j.semcancer.2011.12.003](https://doi.org/10.1016/j.semcancer.2011.12.003). [PubMed: [22202556](https://pubmed.ncbi.nlm.nih.gov/22202556/)].
27. Pandey S, Talib A, Mukeshchand Thakur M, Shah Nawaz Khan M, Bhaisare ML, Gedda G, et al. Tellurium platinate nanowires for photothermal therapy of cancer cells. *J Mater Chem B*. 2016;**4**(21):3713–20. doi: [10.1039/c5tb02127h](https://doi.org/10.1039/c5tb02127h). [PubMed: [32263310](https://pubmed.ncbi.nlm.nih.gov/32263310/)].